Company news
Axsome Therapeutics, Inc. news in 2025
Axsome Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
December 30, 2025
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
December 30, 2025
Axsome Therapeutics to Participate in Upcoming Investor Conferences
November 19, 2025
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
November 5, 2025
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
November 5, 2025
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 2, 2025
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
October 8, 2025
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
October 6, 2025
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
September 16, 2025
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 3, 2025
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
July 20, 2025
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
July 8, 2025
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21
July 6, 2025
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
June 19, 2025
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)
June 17, 2025
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders
June 15, 2025
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
June 11, 2025
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
June 9, 2025
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
June 8, 2025
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
May 27, 2025
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
May 26, 2025
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
May 12, 2025
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 4, 2025
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
April 30, 2025
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
April 7, 2025
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
April 3, 2025
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)
March 31, 2025
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint
March 24, 2025
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
March 5, 2025
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
March 2, 2025
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors
February 23, 2025
Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 17, 2025
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
February 9, 2025
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
January 30, 2025
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
January 29, 2025
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue
January 12, 2025
Calls in 2025
- Axsome Therapeutics (NASDAQ:AXSM) Q3 2025 Earnings Call
Nov 3, 2025
Transcript - Axsome Therapeutics (NASDAQ:AXSM) Q2 2025 Earnings Call
Aug 4, 2025
Transcript - Axsome Therapeutics (NASDAQ:AXSM) Q1 2025 Earnings Call
May 6, 2025
Transcript - Axsome Therapeutics (NASDAQ:AXSM) Q4 2024 Earnings Call
Jan 13, 2025
Transcript
Decks in 2025
- Q3 2025 Earnings Presentation
Earnings · 46 slides · Nov 3, 2025
- Q2 2025 Earnings Presentation
Earnings · 45 slides · Aug 4, 2025
- Q1 2025 Earnings Presentation
Earnings · 26 slides · May 6, 2025
- Q1 2025 Earnings Presentation
Earnings · 45 slides · May 5, 2025
- FY2024 Earnings Presentation
Earnings · 46 slides · Feb 18, 2025